跳至主要内容
临床试验/NCT02553850
NCT02553850已完成不适用

A SURVEY TO STUDY THE CORRELATION BETWEEN THE SERUM LEVELS OF BONE TURNOVER MARKERS AND THE CLINICAL PICTURE IN PATIENTS WITH BREAST CANCER AND BONE METASTASES RECEIVING IBRADONIC ACID TREATMENT

Hoffmann-La Roche0 个研究点目标入组 442 人开始时间: 2007年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
442
主要终点
Beta C-terminal telopeptide (B-CTx) level

研究概览

简要总结

This open non-randomized, single-arm, multicenter, observational study is designed to evaluate the correlation between bone turnover markers and the response to treatment in patients with breast cancer and bone metastases. In this observational study, ibandronate (Bondronat) will be prescribed and used in accordance with the standards of care. Data will be collected for 12 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All criteria in accordance with the Summary of Product Characteristics of Bondronat (ibandronate)
  • Adult patients greater than (>) 18 years of age
  • Histologically confirmed breast cancer
  • Confirmed bone metastasis (by bone scintigraphy, X-ray, computed tomography or magnetic resonance imaging)
  • Life expectancy >6 months
  • No previous bisphosphonate therapy
  • Patients signed written informed consent form before study start

排除标准

  • All criteria in accordance with the Summary of Product Characteristics of Bondronat(ibandronate)
  • Hypersensitivity to the active substance or any of the excipients of Bondronat (ibandronate)
  • Hypersensitivity to bisphosphonates

结局指标

主要结局

Beta C-terminal telopeptide (B-CTx) level

时间窗: 12 months

Treatment response rate

时间窗: 12 months

次要结局

  • Number of patients who died due to progression of breast cancer(12 months)
  • Safety: Incidence of adverse events(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验